Eli Lilly’s Oral Obesity Drug Leads To Over 12% Weight Loss In Late-Stage Study

The investigational once-daily oral pill showed significant efficacy, and a safety and tolerability profile consistent with injectable GLP-1 therapies such as Lilly’s Mounjaro at 72 weeks, the company said.

Eli Lilly and Company (LLY) on Thursday said that its investigational oral weight-loss drug lowered weight by an average of 12.4% in a late-stage study at its highest dose.  

The once-daily oral pill called Orforglipron showed significant efficacy, and a safety and tolerability profile consistent with injectable GLP-1 therapies such as Lilly’s Mounjaro at 72 weeks, the company said. 

Get updates to this developing story <directly on Stocktwits.<